Compare GameStop Corp. (GME) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? GameStop Corp. trades at $26.7 (market cap $13.73B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: GameStop Corp. is far larger — about 14.1× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and GameStop Corp. is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GME | MRVI | |
|---|---|---|
Market Cap | $13.73B | $972.90M |
Volume | 12,710,661 | 4,325,710 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $9.00 |
52-Week Low | $17.87 | $2.83 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $13.01B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.15, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company reported net income of $131.3M in 2025, a significant turnaround from prior losses, and holds a strong cash position of $4.77B. Recent insider buying by CEO Ryan Cohen has driven positive sentiment, with shares gaining 31% over the past month.
The outlook is mixed; strong cash reserves and insider confidence support upside, but revenue declined to $3.82B in 2025, and analyst consensus remains cautious with only 16.7% buy ratings. Key risks include execution challenges in the retail gaming sector and high valuation multiples relative to historical performance.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
